| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8765150 | ITALFARMACO SA | Riluzole aqueous suspensions |
Mar, 2029
(4 years from now) | |
Tiglutik Kit is owned by Italfarmaco Sa.
Tiglutik Kit contains Riluzole.
Tiglutik Kit has a total of 1 drug patent out of which 0 drug patents have expired.
Tiglutik Kit was authorised for market use on 05 September, 2018.
Tiglutik Kit is available in suspension;oral dosage forms.
Tiglutik Kit can be used as a method of treating amyotrophic lateral sclerosis in a patient in need of such treatment, said method comprising administering to said patient an effective amount of a suspension according to claim 1.
The generics of Tiglutik Kit are possible to be released after 12 March, 2029.
Drugs and Companies using
RILUZOLE ingredient
Market Authorisation Date:
05 September, 2018Treatment:
A method of treating amyotrophic lateral sclerosis in a patient in need of such treatment, said method comprising administering to said patient an effective amount of a suspension according to claim 1Dosage:
SUSPENSION;ORAL
How can I launch a generic of TIGLUTIK KIT before its drug patent expiration?
More Information on Dosage
TIGLUTIK KIT family patents
